Effect of transcutaneous aurical vagal nerve stimulation (taVNS) on fatigue in patients with long covid.
- Conditions
- U08.9U09.9U10.9G93.3Personal history of COVID-19, unspecifiedPost COVID-19 condition, unspecifiedMultisystem inflammatory syndrome associated with COVID-19, unspecifiedPostviral fatigue syndrome
- Registration Number
- DRKS00031974
- Lead Sponsor
- niversitätsklinik Knappschaftskrankenhaus Bochum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Z.n. completed Covid infection within the last 18 months
- Fatigue persisting for = 3 months with a score =4 on the FSS fatigue scale
- Age >18
- No depression or depression that has been treated stably for 4 weeks
- Serious psychiatric illness such as schizophrenia
- Acute corona infection
- >8 items on the NGASR suicide questionnaire
- Vagus nerve stimulation or condition vagotomy
- Relevant cardiac disease: bradycardiac cardiac arrhythmia (e.g. sick sinus syndrome), cardiac insufficiency, status post. Heart attack
- Active implant such as cardiac pacemaker, defibrillator, neurostimulator, cochlear implant or drug delivery device and ventricular shunt.
- Inability to understand the study
- Progressive neurological disease (e.g. Parkinson's, MS, epilepsy)
- pregnancy
- Other acute illness associated with fatigue (e.g. cancer, chemotherapy, autoimmune diseases)
- Polyneuropathy
- Presence of a skin condition such as infection, psoriasis or eczema in the treatment area.
- Presence of any anatomical abnormality that prevents the successful insertion of the ear electrode.
- Presence of any serious medical condition that prevents successful participation in the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acceptance of the therapy, effect of taVNS on MFI-20-Score
- Secondary Outcome Measures
Name Time Method Effect of taVNS on BDI and SF36 score<br>